OK Prog. I'll bite on why I think $51.53 for all of CTIX is Hobo Money.

What would you all say has a wider market base for a major novel drug; Hepititus C or a wide range of Cancers?

I know members have compared previously the maket value of Parmasset buyout at a PHASE 2 trial at $137.

I believe it's a valid comparisson CTIX for evaluation for Phase 2 buyout by Big Pharma.

http://www.google.com/url?sa=t&rct=j&...jZWjcYVKFQ

The difference by comparrison CTIX has a wider market 'treatment base' in it's various compounds now in the works then Pharmasset ever did. So all things considered, (and I don't have all the details here and perhaps one of our smart people can put it on a chart), we are worth MORE in buyout valuation in a Phase 2 Buy-out then Pharmasset was at $137.

So Yes, $150. to $180. is my Kool-Aid'ers estimation with all testing passing as expected as discussed with very low tox and strong and lasting patient recovery.

-bunny-